PD-L1≥50%的NSCLC患者一线帕博利珠单抗单药治疗进展后的真实世界结局
这项大型多中心真实世界研究纳入974例PD-L1≥50%的转移性NSCLC患者,接受一线帕博利珠单抗单药治疗。中位随访22.7个月时,中位总生存期为15.8个月。678例疾病进展患者中,55.9%未接受后续治疗,29.2%换用其他方案,14.9%继续帕博利珠单抗(单用或联合局部消融)。真实世界结局劣于KEYNOTE-024试验,进展后治疗不足是主要影响因素。
要点
- PD-L1≥50%的NSCLC一线帕博利珠单抗真实世界OS为15.8个月,劣于KEYNOTE-024。
- 疾病进展后55.9%未接受任何后续治疗,是影响总生存的重要因素。
- 进展后继续帕博利珠单抗联合局部消融较单用帕博利珠单抗延长进展后OS(13.9 vs 7.8个月)。
核心结论
- 真实世界中PD-L1≥50%的NSCLC患者一线帕博利珠单抗单药的结局劣于KEYNOTE-024试验,进展后治疗不足是主要决定因素。
研究设计与样本
- 大型多中心真实世界队列研究,纳入974例PD-L1表达≥50%的转移性NSCLC患者,均接受一线帕博利珠单抗单药治疗。
主要发现
- 中位随访22.7个月(95%CI: 21.6-38.2),全人群中位总生存期为15.8个月(95%CI: 13.5-17.5;548例事件)。
- 678例疾病进展患者中,379例(55.9%)未接受任何后续治疗,359例(52.9%)死亡。
- 进展时198例(29.2%)换用其他方案,101例(14.9%)继续帕博利珠单抗(单用64例[9.4%],联合局部消融37例[5.5%])。
- 经随机病例对照匹配(按ECOG-PS、CNS转移、骨转移和既往最佳缓解),继续帕博利珠单抗联合局部消融组进展后OS显著长于单用组(13.9个月 vs 7.8个月,p=0.0179)。
- 678例进展患者中241例(35.5%)接受二线全身治疗。
关键数值与推荐
- 未接受进展后治疗的患者年龄更大(p=0.0011)、ECOG-PS更差(p<0.0001)且在帕博利珠单抗前使用皮质激素(p=0.0024)。
- 与一线治疗开始时相比,二线治疗开始时患者特征显示年龄<70岁比例显著更高(p=0.0244)、ECOG-PS更差(p<0.0001)以及CNS转移(p=0.0001)、骨转移(p=0.0266)和肝转移(p=0.0148)比例更高。
临床怎么用
- 对PD-L1≥50%的NSCLC患者一线选择帕博利珠单抗单药时,应告知进展后可能无法接受后续治疗的真实世界风险。
- 疾病进展后,继续帕博利珠单抗联合局部消融可能改善生存,尤其适合经过筛选的患者。
- 年龄较大、ECOG-PS较差或使用皮质激素的患者进展后接受治疗的可能性更低,需提前规划支持治疗。
局限性
- 真实世界回顾性设计可能存在选择偏倚和信息偏倚。
- 未报告PD-L1检测方法、治疗决策的具体原因及后续治疗的详细方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment sequencing with first-line immunotherapy, followed by second-line chemotherapy, is still a viable option for NSCLC patients with PD-L1 expression ≥50%. METHODS: We evaluated post-progression treatment pathways in a large real-world cohort of metastatic NSCLC patients with PD-L1 expression ≥ 50% treated with first-line pembrolizumab monotherapy. RESULTS: Overall, 974 patients were included. With a median follow-up of 22.7 months (95%CI: 21.6-38.2), the median overall survival (OS) of the entire population was 15.8 months (95%CI: 13.5-17.5; 548 events). At the data cutoff, among the 678 patients who experienced disease progression, 379 (55.9%) had not received any further treatment, and 359 patients (52.9%) had died. Patients who did not receive post-progression therapies were older (p = 0.0011), with a worse ECOG-PS (p < 0.0001) and were on corticosteroids prior to pembrolizumab (p = 0.0024). At disease progression, 198 patients (29.2%) received a switched approach and 101 (14.9%) received pembrolizumab ByPD either alone (64 [9.4%]) or in combination with local ablative treatments (37 [5.5%]) (LATs). After a random-case control matching according to ECOG-PS, CNS metastases, bone metastases, and (previous) best response to pembrolizumab, patients receiving pembrolizumab ByPD plus LATs were confirmed to have a significantly longer post-progression OS compared to patients receiving pembrolizumab ByPD alone 13.9 months versus 7.8 months (p = 0.0179) 241 patients (35.5%) among the 678 who had experienced PD, received a second-line systemic treatment (regardless of previous treatment beyond PD). As compared to first-line treatment commencement, patients' features at the moment of second-line initiation showed a significantly higher proportion of patients aged under 70 years (p = 0.0244), with a poorer ECOG-PS (p < 0.0001) and having CNS (p = 0.0001), bone (p = 0.0266) and liver metastases (p = 0.0148). CONCLUSIONS: In the real-world scenario NSCLC patients with PD-L1 expression ≥50% treated with first-line single-agent pembrolizumab achieve worse outcomes as compared to the Keynote-024 trial. Poor post-progression outcomes are major determinants of the global results that should be considered when counselling patients for first-line treatment choices.
引用
- Cortellini A, Cannita K, Tiseo M, et al. Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. Eur J Cancer. 2021. PMID: 33721704. doi:10.1016/j.ejca.2021.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。